Birch Grove Capital LP - INTERCEPT PHARMACEUTICALS IN ownership

Quarter-by-quarter ownership
Birch Grove Capital LP ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q2 2021$13,500,000
+16.5%
15,003,000
+7.1%
6.56%
+30.4%
Q1 2021$11,590,000
+46.1%
14,003,000
+40.0%
5.03%
+21.6%
Q4 2020$7,934,000
+116.9%
10,003,000
+122.1%
4.14%
+108.9%
Q3 2020$3,658,0004,503,0001.98%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Silver Point Capital L.P. 57,420,000$44,527,0005.17%
Birch Grove Capital LP 10,003,000$7,934,0004.14%
PenderFund Capital Management Ltd. 9,605,000$9,491,0002.41%
Context Capital Management, LLC 9,887,000$7,671,0001.05%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 57,791,000$45,738,0000.90%
DeepCurrents Investment Group LLC 35,892,000$27,953,0000.74%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 22,977,000$18,267,0000.70%
WHITEBOX ADVISORS LLC 23,150,000$17,847,0000.56%
ADVENT CAPITAL MANAGEMENT /DE/ 27,397,000$21,720,0000.46%
OAKTREE CAPITAL MANAGEMENT LP 19,435,000$15,079,0000.26%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders